Therapeutic strategies for the prevention and treatment of cytomegalovirus infection

Bibliography

• Sester M, Sester U, Gartner B, Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 2002;76:3748-55
   PubMed Web of Science ®Google Scholar
• Khan N, Shariff N, Cobbold M, Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169:1984-92
   PubMed Web of Science ®Google Scholar
• Pourgheysari B, Khan N, Best D, The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007;81:7759-65
   PubMed Web of Science ®Google Scholar
• Elkington R, Walker S, Crough T, Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673-85
   PubMed Web of Science ®Google Scholar
• Pawelec G, Derhovanessian E, Larbi A, Cytomegalovirus and human immunosenescence. Rev Med Virol 2009;19:47-56
   PubMed Web of Science ®Google Scholar
• Khan N, Hislop A, Gudgeon N, Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481-9
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-14
   PubMed Web of Science ®Google Scholar
• Broers AE, van Der Holt R, van Esser JW, Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-5
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Pasquini MC, Gardellini A, Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027-33
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Ainsworth J, Cobbold M, Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97:1232-40
   PubMed Web of Science ®Google Scholar
• Aubert G, Hassan-Walker AF, Madrigal JA, Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001;184:955-63
   PubMed Web of Science ®Google Scholar
• Gratama JW, van Esser JW, Lamers CH, Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-64
   PubMed Web of Science ®Google Scholar
• Hebart H, Daginik S, Stevanovic S, Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99:3830-7
   PubMed Web of Science ®Google Scholar
• Pergam SA, Xie H, Sandhu R, Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients. Biol Blood Marrow Transplant 2012 Mar 3. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wloch MK, Smith LR, Boutsaboualoy S, Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008;197:1634-42
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27:770-81
   PubMed Web of Science ®Google Scholar
• Meyers JD, Reed EC, Shepp DH, Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70-5
   PubMed Web of Science ®Google Scholar
• Prentice HG, Gluckman E, Powles RL, Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. the European Acyclovir for CMV prophylaxis study group. Bone Marrow Transplant 1997;19:129-33
   PubMed Web of Science ®Google Scholar
• Ljungman P, de La Camara R, Milpied N, Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-6
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Bowden RA, Fisher L, Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:5403-10
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284-92
   PubMed Web of Science ®Google Scholar
• Biron KK, Stanat SC, Sorrell JB, Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82:2473-7
   PubMed Web of Science ®Google Scholar
• Einsele H, Reusser P, Bornhauser M, Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002-8
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Zecca M, Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005;90:526-33
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-74
   PubMed Web of Science ®Google Scholar
• Foulongne V, Turriere C, Diafouka F, Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virol 2004;48:51-5
   PubMed Web of Science ®Google Scholar
• Marfori JE, Exner MM, Marousek GI, Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007;38:120-5
   PubMed Web of Science ®Google Scholar
• van der Beek MT, Berger SP, Vossen AC, Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-6
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159-64
   PubMed Web of Science ®Google Scholar
• Scott GM, Weinberg A, Rawlinson WD, Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007;51:89-94
   PubMed Web of Science ®Google Scholar
• Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol 2012;156:559-72
   PubMed Web of Science ®Google Scholar
• Avery RK, Marty FM, Strasfeld L, Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12:489-96
   PubMed Web of Science ®Google Scholar
• Strasfeld L, Lee I, Tatarowicz W, Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010;202:104-8
   PubMed Web of Science ®Google Scholar
• Avery RK, Bolwell BJ, Yen-Lieberman B, Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-5
   PubMed Web of Science ®Google Scholar
• Avery RK, Mossad SB, Poggio E, Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
   PubMed Web of Science ®Google Scholar
• John GT, Manivannan J, Chandy S, A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005;37:4303-5
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Lampert B, Collins DJ, Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010;202:1492-9
   PubMed Web of Science ®Google Scholar
• Wan WB, Beadle JR, Hartline C, Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005;49:656-62
   PubMed Web of Science ®Google Scholar
• Ciesla SL, Trahan J, Wan WB, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59:163-71
   PubMed Web of Science ®Google Scholar
• Lischka P, Hewlett G, Wunberg T, In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54:1290-7
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E, First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84
   PubMed Web of Science ®Google Scholar
• Adjuik M, Babiker A, Garner P, Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363:9-17
   PubMed Web of Science ®Google Scholar
• Efferth T, Marschall M, Wang X, Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 2002;80:233-42
   PubMed Web of Science ®Google Scholar
• Kaptein SJ, Efferth T, Leis M, The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006;69:60-9
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Chou S, Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008;46:1455-7
   PubMed Web of Science ®Google Scholar
• Lau PK, Woods ML, Ratanjee SK, Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011;52:279
   PubMed Web of Science ®Google Scholar
• Wolf DG, Shimoni A, Resnick IB, Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6
   PubMed Web of Science ®Google Scholar
• Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009;9:725-36
   PubMed Web of Science ®Google Scholar
• Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008;41:193-8
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-7
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009;49:1851-60
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-22
   PubMed Web of Science ®Google Scholar
• Micklethwaite K, Hansen A, Foster A, Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:707-14
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86
   PubMed Web of Science ®Google Scholar
• Yao J, Bechter C, Wiesneth M, Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 2008;46:e96-105
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011;51:591-9
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010;116:4360-7
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011;52:49-57
   PubMed Web of Science ®Google Scholar
• Zandvliet ML, van Liempt E, Jedema I, Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy 2010;12:933-44
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Vera JF, Rooney CM, Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 2011;51
   PubMedGoogle Scholar
• Zandvliet ML, van Liempt E, Jedema I, Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 2011;34:307-19
   PubMedGoogle Scholar
• Lugthart G, Albon SJ, Ricciardelli I, Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother 2012;35:42-53
   PubMed Web of Science ®Google Scholar
• Khanna N, Stuehler C, Conrad B, Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011;118:1121-31
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz CR, Savoldo B, Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114:1958-67
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Martinez C, Leung K, Phase I study to improve virus-specific immune reconstitution after cord blood transplantation using cord blood-derived virus-specific cytotoxic T lymphocytes. ASH Annual Meeting Abstracts 2011;118:155
   Google Scholar
• Schub A, Schuster IG, Hammerschmidt W, CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 2009;183:6819-30
   PubMed Web of Science ®Google Scholar
• Full F, Lehner M, Thonn V, T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol 2010;84:4083-8
   PubMed Web of Science ®Google Scholar